our capabilities
Uniquely integrated formulation, device and development capabilities
We effectively integrate all technologies and disciplines required to deliver an inhaled product.
Investors
Share price
Latest results
- 10 Sep 2019 | Vectura NewsInterim results for the six months ended 30 June 2019
- 26 Mar 2019 | Vectura NewsPreliminary results for the year ended 31 December 2018
Vectura news
Sep 13, 2019, 10:53 AM
Sep 10, 2019, 7:05 AM
Sep 10, 2019, 7:05 AM
Jul 16, 2019, 11:07 AM
Investment case
1
Differentiated inhalation development capabilities
2
In-market product cash flow generation
3
Focused R&D strategy with pipeline progression and partnering potential
4
Focus on Operational Excellence
5
Strong cash flow generation and capital discipline